LEADER 03789nam  2200565   450 
001 9910464794103321
005 20200520144314.0
010   $a88-97419-48-8
035   $a(CKB)3710000000118108
035   $a(EBL)3034685
035   $a(SSID)ssj0001399529
035   $a(PQKBManifestationID)11867888
035   $a(PQKBTitleCode)TC0001399529
035   $a(PQKBWorkID)11450653
035   $a(PQKB)11170189
035   $a(MiAaPQ)EBC3034685
035   $a(Au-PeEL)EBL3034685
035   $a(CaPaEBR)ebr10960571
035   $a(OCoLC)880938340
035   $a(EXLCZ)993710000000118108
100   $a20141106d2013      uy|            0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aMultiple sclerosis $ea guide to pharmacologic treatment /$fD. Ontaneda
205   $aFirst edition.
210  1$aTorino, Italy :$cSEEd,$d2013.
215   $a1 online resource (150 p.)
300   $aDescription based upon print version of record.
311   $a88-97419-47-X 
320   $aIncludes bibliographical references.
327   $a""Title Page""; ""Colophon""; ""Table of Contents""; ""Section I. Introduction""; ""Scope""; ""New Therapies and Risks""; ""Overview of Multiple Sclerosis""; ""Basic pathogenesis""; ""Disease forms""; ""Approach to treatment""; ""Goals of treatment""; ""Challenges""; ""References""; ""Section II. Disease Modifying Agents for Multiple Sclerosis""; ""Interferon for MS""; ""Introduction""; ""Mechanism of Action""; ""Efficacy""; ""Safety and Risks""; ""Conclusions""; ""References""; ""Glatiramer acetate for MS""; ""Introduction""; ""Mechanism of Action""; ""Efficacy""; ""Safety and Risks""
327   $a""Conclusions""""References""; ""Mitoxantrone for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Natalizumab for MS""; ""Introduction""; ""Mechanism of Action""; ""Efficacy""; ""Safety and Risks""; ""Conclusions""; ""References""; ""Fingolimod for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Teriflunomide for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusion""; ""References""
327   $a""Dimethyl fumarate for MS""""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Section III. Treatment of relapses""; ""Defining Relapses""; ""Introduction""; ""Relapse symptoms""; ""MRI in MS Relapses""; ""Natural History of MS Relapses""; ""References""; ""Treatment of MS relapses""; ""Introduction""; ""Corticosteroids (CS) and ACTH""; ""Plasma exchange""; ""IVIG""; ""References""; ""Section IV. Emerging therapies for multiple sclerosis""; ""Laquinimod for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""
327   $a""Safety and risks""""Conclusions""; ""References""; ""Alemtuzumab for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Daclizumab for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Ocrelizumab and Rituximab for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Author""
606   $aMultiple sclerosis$xTreatment
606   $aPharmacology
608   $aElectronic books.
615  0$aMultiple sclerosis$xTreatment.
615  0$aPharmacology.
700   $aOntaneda$b D.$0920527
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910464794103321
996   $aMultiple sclerosis$92064566
997   $aUNINA